UY30391A1 - Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c - Google Patents

Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c

Info

Publication number
UY30391A1
UY30391A1 UY30391A UY30391A UY30391A1 UY 30391 A1 UY30391 A1 UY 30391A1 UY 30391 A UY30391 A UY 30391A UY 30391 A UY30391 A UY 30391A UY 30391 A1 UY30391 A1 UY 30391A1
Authority
UY
Uruguay
Prior art keywords
hepatitis
aciclic
oxym
compound
protease inhibitors
Prior art date
Application number
UY30391A
Other languages
English (en)
Inventor
Zhe Wang
Ying Sun
Yat Sun Or
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of UY30391A1 publication Critical patent/UY30391A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Abstract

Compuestos de formula I o sus sales aceptables para uso farmacéutico, ésteres, o prodrogas: que inhiben la actividad de la serina proteasa, particularmente la actividad de la proteasa del virus de la hepatitis C (HCV) NS3-NS4A. En consecuencia, interfieren con el ciclo de vida del virus de la hepatitis C y también son utiles como agentes antivirales. Composiciones farmacéuticas que comprenden los compuestos mencionados para su administracion a un sujeto que sufra de una infeccion por HCV. Métodos para tratar una infeccion por HCV en un sujeto administrando una composicion farmacéutica que comprende los compuestos de la presente invencion.
UY30391A 2006-06-06 2007-06-06 Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c UY30391A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81146406P 2006-06-06 2006-06-06
US50338506A 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
UY30391A1 true UY30391A1 (es) 2008-01-31

Family

ID=38832101

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30391A UY30391A1 (es) 2006-06-06 2007-06-06 Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c

Country Status (5)

Country Link
AR (1) AR063942A1 (es)
CL (1) CL2007001630A1 (es)
TW (1) TW200815481A (es)
UY (1) UY30391A1 (es)
WO (1) WO2007146695A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8426360B2 (en) 2007-11-13 2013-04-23 Enanta Pharmaceuticals, Inc. Carbocyclic oxime hepatitis C virus serine protease inhibitors
WO2009073713A1 (en) 2007-12-05 2009-06-11 Enanta Pharmaceuticals, Inc. Oximyl macrocyclic derivatives
WO2009076166A2 (en) 2007-12-05 2009-06-18 Enanta Pharmaceuticals, Inc. Oximyl hcv serine protease inhibitors
EP2224920A4 (en) 2007-12-06 2012-05-09 Enanta Pharm Inc PROCESS FOR THE PREPARATION OF MACROCYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
JP2011506472A (ja) 2007-12-14 2011-03-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状オキシミルｃ型肝炎セリンプロテアーゼ阻害剤
WO2009085978A1 (en) 2007-12-20 2009-07-09 Enanta Pharceuticals, Inc. Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors
US8372802B2 (en) 2008-03-20 2013-02-12 Enanta Pharmaceuticals, Inc. Fluorinated macrocyclic compounds as hepatitis C virus inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
CN104662000B (zh) 2012-05-15 2018-08-17 索伦托医疗有限公司 药物偶联物及其偶联方法和用途
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
CA3025253A1 (en) 2016-06-21 2017-12-28 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
CN110904121B (zh) * 2019-12-17 2022-11-29 南京农业大学 易感基因sr30在改良农作物抗性中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273851B2 (en) * 2003-06-05 2007-09-25 Enanta Pharmaceuticals, Inc. Tri-peptide hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
CL2007001630A1 (es) 2008-02-08
WO2007146695A1 (en) 2007-12-21
TW200815481A (en) 2008-04-01
AR063942A1 (es) 2009-03-04

Similar Documents

Publication Publication Date Title
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
UY30527A1 (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
ECSP10010254A (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
MX2010010276A (es) Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
ECSP088258A (es) Inhibidores de serina proteasas
MX2010006518A (es) Inhibidores de serina proteasa de hepatitis c de oximil macrociclica.
MX2010006210A (es) Inhibidores de serina proteasa de hcv de tripeptido fluorado.
MX2010006209A (es) Derivados de quinoxalinilo.
MX2010008109A (es) Tripéptidos difluorizados como inhibidores de proteasa de serina de virus de hepatitis c (hcv).
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170627